Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

Fate Therapeutics

Status

Terminated

Conditions

Microsatellite Instability

Small-cell Lung Cancer

Squamous Cell Carcinoma

Melanoma

Urothelial Carcinoma

Advanced Solid Tumor

Pancreas Cancer

HER2-positive Breast Cancer

EGFR Positive Solid Tumor

Merkel Cell Carcinoma

Gastric Cancer

Hepatocellular Carcinoma

Lymphoma

Renal Cell Carcinoma

Head and Neck Cancer

Cervical Cancer

NSCLC

Colorectal Cancer

Treatments

Genetic: Allogeneic natural killer (NK) cell

Study type

Observational

Funder types

Industry

Identifiers

NCT04106167

FT-003

Details and patient eligibility

About

Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study. Subjects will automatically enroll into study FT-003 once they have withdrawn or complete the parent interventional study.

The purpose of this study is to provide long-term safety and survival data for subjects who have participated in the parent study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study.

Full description

This is a multicenter, non-interventional, observation study designed to provide long-term safety and efficacy data on subjects who have participated in a prior Fate Therapeutics interventional study of FT500 cellular immunotherapy. Subjects will be contacted every six months (± one month), beginning six months after subject completion or withdrawal from the FT500-101 study.

Enrollment

20 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subjects who received an allogeneic, iPSC-derived NK cell in a Fate Therapeutics interventional study
Subjects who have provided Informed consent prior to their study participation

Exclusion criteria